Diplomat acquires Burman’s Specialty Pharmacy

FLINT, Mich. — Diplomat Pharmacy announced Friday that it had acquired the Pennsylvania-based Burman’s Specialty Pharmacy for $72.8 million in cash and $10 million in Diplomat common stock. The acquisition has expanded Diplomat’s hepatitis C specialty services, as Burman’s individualized patient care is focused primarily on those with Hepatitis C.

“Burman's shares our strong commitment to patient care,” Diplomat CEO and chairman Phil Hagerman said. “We acquired Burman's to enhance our targeted clinical management programs, utilize its innovative hepatitis C technology platform and strong payer network, and increase our presence in the U.S. mid-Atlantic region.”

Burman’s uses HealthTrac software, which allows pharmacists and providers to collaborate more on patient care and can be especially helpful for patients with hepatitis C.

“Diplomat's patient-centric focus echoes our own approach,” Steve Burman, president and CEO of Burman’s said. “We pride ourselves on improving patient care with innovative technology. HealthTrac opens the lines of communication between all healthcare professionals involved to improve treatment efficiency in an effort to both improve results and reduce costs. Diplomat shares that vision and puts it into practice with high-touch patient care.”

“We believe the HealthTrac technology will significantly expand our hepatitis C services across our national footprint,” Hagerman said.